Get the Stockscreener App
3.13
3.07%
-0.13
Nrx Pharmaceuticals Inc stock is traded at $3.13, with a volume of 70,959.
It is down -3.07% in the last 24 hours and up +19.70% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$3.26
Open:
$3.25
24h Volume:
70,959
Relative Volume:
0.28
Market Cap:
$60.17M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-0.7825
EPS:
-4
Net Cash Flow:
$-21.66M
1W Performance:
-1.86%
1M Performance:
+19.70%
6M Performance:
+43.64%
1Y Performance:
+22.48%
1-Day Range:
$3.10
$3.25
1-Week Range:
$3.10
$3.53
52-Week Range:
$1.10
$6.01
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Compare NRXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
3.13 | 60.17M | 0 | -30.15M | -21.66M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.08 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
537.07 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.24 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
557.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.47 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Initiated | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
New to The Street's Show #672 Airs Tonight on Fox Business Network at 10:30 PM EST - The Joplin Globe
NRx Pharmaceuticals (NASDAQ: NRXP) Forms Investor Relations Partnership With astr Partners - financial-news.co.uk
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partners - StreetInsider
NRx Pharmaceuticals Taps Top Biotech IR Firm ahead of Critical FDA Filings and Clinic Acquisitions - Stock Titan
New to The Street Episode #671 Airs Tonight on Bloomberg Television at 6:30 PM EST Featuring FLOKI, Arrive AI (NASDAQ: ARAI), Health In Tech (NASDAQ: HIT), Vita Bella, and NRX Pharmaceuticals (NASDAQ: NRXP) - Livingston Daily
Safety scares and trial misses drag down neuro biotechs into Q2 - BioWorld MedTech
NRx Pharmaceuticals CEO Set to Reveal Latest Advances at Major Neuroscience Investment Conference - Stock Titan
Squarepoint Ops LLC Makes New Investment in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) - Defense World
NRX Pharmaceuticals Submits FDA Application for NRX-100 - TipRanks
New to The Street Signs National Media Agreement with NRx Pharmaceuticals for 12-Part Broadcast Series Across TV, Digital, and Outdoor Platforms - USA Today
NRx Pharmaceuticals’ (NRXP) Buy Rating Reaffirmed at D. Boral Capital - Defense World
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network - Yahoo Finance
NRx Pharmaceuticals (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network - Barchart.com
NRX Pharmaceuticals: Strategic Positioning and Market Potential Drive Buy Rating - TipRanks
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Investor Event at Mar-A-Lago Club on May 8, 2025 - mx.advfn.com
NRx Pharmaceuticals files for preservative-free ketamine By Investing.com - Investing.com South Africa
$750 Million Market Projected to Reach $3.35 Billion Globally - openPR.com
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files ANDA for Preservative-Free IV Ketamine - Yahoo Finance
Why Ciena Stock Is Plummeting Today - The Globe and Mail
$750 Million Market Projected to Reach $3.35 Billion Globally in 2034 for Abbreviated New Drug Application Filed on Preservative-Free IV Ketamine: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Barchart.com
$750 Million Market Projected to Reach $3.35 Billion Globally in 2034 for Abbreviated New Drug Application Filed on Preservative-Free IV Ketamine: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) | FinancialContent - FinancialContent
NRx Pharmaceuticals (NASDAQ: NRXP) Files ANDA for Preservative-Free IV Ketamine - TipRanks
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine - GuruFocus
NRx Pharmaceuticals files for preservative-free ketamine - Investing.com Australia
NRXP Advances FDA Application for IV Ketamine With Preservative-Free Formulation | NRXP Stock News - GuruFocus
NRX Pharmaceuticals Seeks FDA's Priority Review for Preservative-Free IV Ketamine - MarketScreener
Why Overall Consumer Confidence Is Critical to the Markets You Follow - The Globe and Mail
Public market insider buying at Tourmaline Oil (TOU) - The Globe and Mail
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Acquires Kadima Institute to Launch $100M Psychiatry Clinic Network - MSN
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Announces $10.3M Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval - Yahoo Finance
NRx Pharmaceuticals (NASDAQ: NRXP) Announces $10.3M Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval - TipRanks
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition - Yahoo Finance
NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition - financial-news.co.uk
Analysts Set NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Target Price at $28.50 - Defense World
Stocktwits Spotlight: NRx, CVS, ReShape Lead Weekly Jump In Health Care Stock Chatter - MSN
NRX Pharmaceuticals Announces $7.8M Debt Financing Deal - TipRanks
NRx Pharmaceuticals (NASDAQ: NRXP) to Present at Wall Street Conference on May 21 - financial-news.co.uk
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) to Present at Wall Street Conference on May 21 - Yahoo Finance
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.31%
2.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):